SCHEMBL879437

SCHEMBL879437

Cc1ncc(C(=O)Nc2nc(-c3ccco3)c(C(=O)C3CCOCC3)s2)cn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 7/20 0.46
KDM4E B2RXH2 4/20 0.46
ALDH1A1 P00352 4/20 0.46
MEN1 O00255 3/20 0.46
POLB P06746 3/20 0.46
KMT2A Q03164 3/20 0.46
PKM P14618 2/20 0.46
LMNA P02545 2/20 0.46
MAPT P10636 2/20 0.46
USP2 O75604 2/20 0.45
PLA2G1B P04054 1/20 0.44
ATG4B Q9Y4P1 1/20 0.44
HSP90AA1 P07900 1/20 0.44
ADORA2A P29274 7/20 0.43
ADORA1 P30542 7/20 0.43
ADORA3 P0DMS8 2/20 0.40
TDP1 Q9NUW8 2/20 0.39
NPC1 O15118 4/20 0.39
RAB9A P51151 4/20 0.39
HPGD P15428 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18801169 0.91 L3MBTL1 (0.45) L3MBTL1KDM4EALDH1A1MEN1POLB
Sipagladenant SCHEMBL879438 0.91 L3MBTL1 (0.47) L3MBTL1KDM4EALDH1A1MEN1POLB
SCHEMBL1677312 0.91 L3MBTL1 (0.46) L3MBTL1KDM4EALDH1A1MEN1POLB
SCHEMBL19075005 0.90 L3MBTL1 (0.44) L3MBTL1KDM4EALDH1A1MEN1POLB
SCHEMBL846810 0.89 L3MBTL1 (0.43) L3MBTL1KDM4EALDH1A1MEN1POLB
SCHEMBL1255617 0.89 L3MBTL1 (0.51) L3MBTL1KDM4EALDH1A1MEN1POLB
SCHEMBL10331934 0.88 L3MBTL1 (0.46) L3MBTL1KDM4EALDH1A1MEN1POLB
SCHEMBL846371 0.88 L3MBTL1 (0.44) L3MBTL1KDM4EALDH1A1MEN1POLB
SCHEMBL1255678 0.88 ALDH1A1 (0.52) L3MBTL1KDM4EALDH1A1MEN1POLB
SCHEMBL1254725 0.87 L3MBTL1 (0.45) L3MBTL1KDM4EALDH1A1MEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3822269-A1 PRODUCTION METHOD OF THIAZOLE DERIVATIVE Kyowa Kirin Co., Ltd. (JP) 2021-05-19 EP disclosed
US-10894790-B2 Production method of thiazole derivative KYOWA KIRIN CO., LTD (JP) 2021-01-19 US disclosed
US-20200247798-A1 THERAPEUTIC AGENT FOR ANXIETY DISORDERS KYOWA KIRIN CO LTD (JP) 2020-08-06 US disclosed
US-20200216438-A1 PRODUCTION METHOD OF THIAZOLE DERIVATIVE KYOWA KIRIN CO LTD (JP) 2020-07-09 US disclosed
US-10407440-B2 Therapeutic agent for motor disorders KYOWA HAKKO KIRIN CO., LTD. (JP) 2019-09-10 US disclosed
US-20190144438-A1 PRODUCTION METHOD OF THIAZOLE DERIVATIVE KYOWA KIRIN CO., LTD. (JP) 2019-05-16 US disclosed
EP-2433938-B1 THERAPEUTIC AGENT FOR MOTOR DISORDERS KYOWA HAKKO KIRIN CO LTD (JP) 2018-04-18 EP disclosed
US-20180002326-A1 PRODUCTION METHOD OF THIAZOLE DERIVATIVE KYOWA KIRIN CO., LTD. (JP) 2018-01-04 US disclosed
EP-2564871-B1 Therapeutic Agent for Migraine KYOWA HAKKO KIRIN CO LTD (JP) 2017-11-15 EP disclosed
US-20170275296-A1 THERAPEUTIC AGENT FOR MOTOR DISORDERS KYOWA KIRIN CO., LTD. (JP) 2017-09-28 US disclosed
WO-2011027805-A1 THERAPEUTIC AGENT FOR MOOD DISORDERS 協和発酵キリン株式会社 (JP) 2011-03-10 WO disclosed
WO-2011027806-A1 THERAPEUTIC AGENT FOR ANXIETY DISORDERS 協和発酵キリン株式会社 (JP) 2011-03-10 WO disclosed
US-7880013-B2 Thiazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-02-01 US disclosed
WO-2010126082-A1 THERAPEUTIC AGENT FOR MOTOR DISORDERS 協和発酵キリン株式会社 (JP) 2010-11-04 WO disclosed
US-20100256361-A1 THIAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 US disclosed
US-20100152162-A1 THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-06-17 US disclosed
US-7718808-B2 Thiazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-05-18 US disclosed
EP-1921077-A1 AGENT FOR TREATING AND/OR PREVENTING SLEEP DISORDER KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-05-14 EP disclosed
US-20070105919-A1 adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-05-10 US disclosed
EP-1700856-A1 THIAZOLE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-09-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10407440-B2 Therapeutic agent for motor disorders DDT, COMT, SLC6A3 L3MBTL1 699/4885KDM4E 4721/4885ALDH1A1 216/4885
US-20190144438-A1 PRODUCTION METHOD OF THIAZOLE DERIVATIVE ADORA2A, HTR1A, ADORA2B L3MBTL1 1740/4885KDM4E 3630/4885ALDH1A1 422/4885
US-20100256361-A1 THIAZOLE DERIVATIVES ADORA2A, ADORA3, ADORA1 L3MBTL1 2618/4885KDM4E 4728/4885ALDH1A1 1290/4885
US-20170275296-A1 THERAPEUTIC AGENT FOR MOTOR DISORDERS DDT, COMT, SLC6A3 L3MBTL1 699/4885KDM4E 4721/4885ALDH1A1 216/4885
US-20200216438-A1 PRODUCTION METHOD OF THIAZOLE DERIVATIVE ADORA2A, HTR1A, ADORA2B L3MBTL1 1740/4885KDM4E 3630/4885ALDH1A1 422/4885
US-20070105919-A1 adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders ADORA2A, ADORA3, ADORA1 L3MBTL1 2473/4885KDM4E 4715/4885ALDH1A1 2843/4885
US-20180002326-A1 PRODUCTION METHOD OF THIAZOLE DERIVATIVE ADORA2A, HTR1A, ADORA2B L3MBTL1 1740/4885KDM4E 3630/4885ALDH1A1 422/4885
US-10894790-B2 Production method of thiazole derivative ADORA2A, HTR1A, ADORA2B L3MBTL1 1740/4885KDM4E 3630/4885ALDH1A1 422/4885
US-20200247798-A1 THERAPEUTIC AGENT FOR ANXIETY DISORDERS TAAR1, SLC6A1, GABBR1 L3MBTL1 1461/4885KDM4E 3799/4885ALDH1A1 32/4885
US-20100152162-A1 THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER HCRTR1, MTNR1A, HCRTR2 L3MBTL1 1732/4885KDM4E 2896/4885ALDH1A1 638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.